Jamie Skrove, DO
Gastroenterology · Cheyenne, WYNPI 1033524095
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.5% of the total across 217 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 26 manufacturers reported payments, led by AbbVie at 27.5% of the total. 2025 is the largest year on record at $1,264, 4.4 times the $285 reported in 2019.
Across 217 payments — averaging $23.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Takeda Pharmaceuticals U.S.A., Inc.$913
- Johnson & Johnson$512
- Gilead$364
- Regeneron Healthcare Solutions, Inc.$295
- Sanofi$219
- plus $1K from 20 others
What the payments were for
- Food & beverage$4,94197%
- Education$842%
- Gifts$441%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 64 | $1,394 |
| Takeda Pharmaceuticals U.S.A., Inc. | 44 | $913 |
| Johnson & Johnson | 22 | $512 |
| Gilead | 10 | $364 |
| Regeneron Healthcare Solutions, Inc. | 13 | $295 |
| Sanofi | 9 | $219 |
| Medtronic | 4 | $201 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 11 | $184 |
| Pfizer | 4 | $120 |
| Laborie Medical Technologies Corp. | 1 | $116 |
| Intercept Pharmaceuticals, Inc. | 4 | $97 |
| Braintree Laboratories, Inc. | 6 | $90 |
| Madrigal Pharmaceuticals | 3 | $81 |
| Bristol Myers Squibb | 1 | $74 |
| Conmed Corporation | 3 | $71 |
| Phathom Pharmaceuticals, Inc. | 4 | $68 |
| Olympus America Inc. | 2 | $46 |
| Lilly USA, LLC | 2 | $41 |
| Nestle Healthcare Nutrition Inc. | 2 | $36 |
| Merck | 2 | $35 |
| Digestive Care, Inc. | 1 | $28 |
| Enterra Medical, Inc. | 1 | $23 |
| Novo Nordisk | 1 | $18 |
| Daiichi Sankyo Inc. | 1 | $14 |
| Redhill Biopharma Inc. | 1 | $14 |
| QOL Medical, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few gastroenterology providers in Wyomingto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 15 | $172,829 |
| OcalivaObeticholic Acid | 12 | $113,835 |
| CreonLipase/Protease/Amylase | 14 | $48,835 |
| ZenpepLipase/Protease/Amylase | 15 | $48,000 |
| Budesonide DrBudesonide | 43 | $6,071 |
| MovantikNaloxegol Oxalate | 12 | $4,904 |
| Mesalamine | 13 | $3,310 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 19 | $3,063 |
| Pantoprazole Sodium | 243 | $1,852 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 61 | $966 |
| Omeprazole | 67 | $710 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 39 | $600 |
| CholestyramineCholestyramine (With Sugar) | 13 | $549 |
| Sucralfate | 26 | $534 |
| Doxycycline Hyclate | 16 | $408 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Intercept Pharmaceuticals, Inc.Ocaliva | $97 | $113,83512 claims |
| AbbVieCreon | $1,394 | $48,83514 claims |
| Redhill Biopharma Inc.Movantik | $14 | $4,90412 claims |
| Braintree Laboratories, Inc.Sutab | $90 | $3,06319 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few gastroenterology providers in Wyomingon file to place this against a meaningful peer group, so we don't.
Other gastroenterology in Cheyenne
- Scott McRaeCheyenne$2K
- Charles KuckelCheyenne$440
- Kenneth KranzCheyenne$355
- Chad CooperCasper$5K
- Raoul JoubranCasper$5K
- Phillip KrmpotichCasper$5K
- Jeffrey CloudCasper$3K
- William ShearCasper$3K
- Kent KatzCasper$2K
- Luis ArmstrongCasper$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.